Radiotheranostics in oncology: current challenges and emerging opportunities
Structural imaging remains an essential component of diagnosis, staging and response
assessment in patients with cancer; however, as clinicians increasingly seek to …
assessment in patients with cancer; however, as clinicians increasingly seek to …
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …
[HTML][HTML] Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Pavel, K Öberg, M Falconi, EP Krenning, A Sundin… - Annals of …, 2020 - Elsevier
Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …
may occur at many different disease sites. Most frequently, these neoplasms occur in the …
Advances in PET imaging of cancer
J Schwenck, D Sonanini, JM Cotton… - Nature Reviews …, 2023 - nature.com
Molecular imaging has experienced enormous advancements in the areas of imaging
technology, imaging probe and contrast development, and data quality, as well as machine …
technology, imaging probe and contrast development, and data quality, as well as machine …
Radiotheranostics: a roadmap for future development
Radiotheranostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid
development over the past decade. Although some formulations are already approved for …
development over the past decade. Although some formulations are already approved for …
Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology
JF Gomes Marin, RF Nunes, AM Coutinho… - Radiographics, 2020 - pubs.rsna.org
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …
[HTML][HTML] European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease
S Grozinsky‐Glasberg, J Davar, J Hofland… - Journal of …, 2022 - ncbi.nlm.nih.gov
1. MATERIALS AND METHODS Data regarding the diagnosis, management, and follow‐up
of carcinoid syndrome (CS) and carcinoid heart disease (CHD) were identified by searches …
of carcinoid syndrome (CS) and carcinoid heart disease (CHD) were identified by searches …
The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors
This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …
Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms
Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …